Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 11 Show results per page	View Search Criteria \| Help With Results

Last Modified: 8/21/2008 First Published: 9/1/2001


1.		Phase III Randomized Study of Consolidation Therapy With or Without Strontium Chloride Sr 89 After Induction Chemotherapy in Patients With Androgen-Independent Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				Any age				NCI				MDA-ID-00156 NCI-3410, 3410, NCT00024167


2.		A Phase III Trial of ZD4054 (Endothelin A Antagonist) in Non-Metastatic Hormone Resistant Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Pharmaceutical / Industry				D4320C00015 NCT00626548

Last Modified: 12/14/2007 First Published: 9/26/2007


3.		Phase I/II Study of Calcitriol, Ketoconazole, and Hydrocortisone in Patients With Advanced or Recurrent Androgen-Independent Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				NCI				RPCI-I-68905 I 68905, NCT00536991


4.		Docetaxel Combined With Ketoconazole in Treatment of Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Other				BR01/07/05 NCT00212095


5.		Maximal Suppression of the Androgen Axis in Clinically Localized Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Other				05-8538-V 01 FHCRC-05026, NCT00298155

Last Modified: 5/24/2008 First Published: 4/6/2007


6.		Phase II Study of Ketoconazole, Hydrocortisone, and Lenalidomide in Patients With Prostate Cancer That Progressed After Androgen Deprivation Therapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Biomarker/Laboratory analysis, Treatment				Active				18 and over				NCI, Pharmaceutical / Industry				CASE-12805 CASE 12805, CELGENE-CASE-12805, NCT00460031


7.		Effect of Ketoconazole Inhibition of CYP3A on Urinary Excretion of Docetaxel

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Biomarker/Laboratory analysis, Treatment				Active				18 and over				Other				PK01/01/06 NCT00697437

Last Modified: 5/16/2007 First Published: 6/1/2002


8.		Phase I Study of Ketoconazole and Docetaxel in Patients With Metastatic Androgen-Independent Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Active				18 and over				NCI				NCI-02-C-0149 NCT00039221


9.		Study of Rapamycin Plus Ketoconazole in Advanced Cancers

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Active				18 and over				Other				UCIRB 13274B NCT00708591


10.		Phase 1 Study of the Effect of Ketoconazole on the PK of Multiple Doses of Cediranib in Patients With Solid Tumours

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Active				18 and over				Pharmaceutical / Industry				D8480C00020 EUDRACT number 2008-002271-27, NCT00750425

Select All on One Page


					1 2 Next >

| | | | | | | |

A Service of the National Cancer Institute